Factors associated with the hospitalization during symptomatic breakthrough infection after a third vaccination dose
Variables | BI needing hospitalization (N=12) | BI without hospitalization (N=52) | Univariable | Multivariable |
|||||
---|---|---|---|---|---|---|---|---|---|
HR | 95% CI | HR | 95% CI | ||||||
Age, mean±SD, yrs | 49.7±18.0 | 48.3±13.6 | 1.01 | 0.96–1.06 | 0.766 | ||||
Male sex, N (%) | 8 (66.7) | 26 (50.0) | 2.00 | 0.56–8.26 | 0.303 | 5.42 | 0.71–41.37 | 0.103 | |
Body mass index, mean±SD, kg/m2 | 21.4±2.5 | 23.6±3.8 | 0.83 | 0.67–1.00 | 0.070 |
0.71 | 0.50–1.01 | 0.056 | |
Dialysis duration, median (IQR), month | 50.5 (7.2–76.3) | 5.8 (0–29.5) | 1.01 | 1.00–1.03 | 0.057 |
||||
Time from third dose to infection, mean±SD, days | 62.8±33.9 | 85.4±24.9 | 0.97 | 0.95–0.99 | 0.017 |
0.97 | 0.94–1.00 | 0.076 | |
Post-third dose anti-spike IgG titer <200 AU/mL, N (%) | 11 (91.7) | 20 (38.5) | 17.6 | 3.07–334.00 | 0.008 |
36.38 | 2.69–492.60 | 0.007 |
*The multivariable logistic regression model included sex, age, and factors with
†Post-booster anti-RBD IgG titer was <200 AU/mL.
Abbreviations: BI, breakthrough infection; IQR, interquartile range; RBD, receptor-binding domain.
© Ann Lab Med